PDF(Pubmed)
Abstract：
Benign and low-grade malignant bone tumours are often treated with curettage and filling of the resultant defect using any of a number of materials, including autologous bone grafts, allografts, or synthetic materials. The objective of this study was to report our experience using a synthetic bone graft substitute in these patients. Ten consecutive cases (four males, six females; mean age, 36 years) of benign bone tumours were treated surgically at a tertiary musculoskeletal oncology centre, between 2019 and 2021. Following curettage, the contained defects were managed with injectable beta-tricalcium phosphate/calcium sulfate (GeneX; Biocomposites Ltd., Keele, UK). The desired outcomes were early restoration of function and radiographic evidence of healing. No other graft materials were used in any of the patients. The mean follow-up was 24 months (range, 20-30 months). All patients in this series (100%) demonstrated radiographic evidence of healing and resumed their daily living activities. There were no tumour recurrences and no complications were encountered with the use of GeneX. In patients with contained defects following curettage of benign bone tumours, we found GeneX to be a safe and effective filling agent. These findings contrast with some existing studies that have reported local complications with the use of injectable beta-tricalcium phosphate/calcium sulfate.
摘要：
良性和低度恶性骨肿瘤通常使用多种材料中的任何一种进行刮擦和填充所产生的缺损。包括自体骨移植,同种异体移植,或合成材料。这项研究的目的是报告我们在这些患者中使用合成骨移植替代品的经验。连续10例(4例男性，六名女性；平均年龄，36年）的良性骨肿瘤在三级肌肉骨骼肿瘤中心进行了手术治疗，2019年至2021年。刮宫后,用可注射的β-磷酸三钙/硫酸钙管理包含的缺陷(GeneX;BiocompositiesLtd.，基尔,英国）。期望的结果是功能的早期恢复和愈合的影像学证据。任何患者均未使用其他移植材料。平均随访时间为24个月(范围，20-30个月）。该系列中的所有患者（100％）都显示出治愈的影像学证据，并恢复了日常生活活动。使用GeneX没有肿瘤复发，也没有遇到并发症。在良性骨肿瘤刮除后存在缺陷的患者中，我们发现GeneX是一种安全有效的填充剂.这些发现与一些现有研究相反，这些研究报告了使用可注射的β-磷酸三钙/硫酸钙的局部并发症。
